These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1023 related items for PubMed ID: 16238900
1. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Diener HC. Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900 [Abstract] [Full Text] [Related]
2. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Diener HC, Gendolla A, Gebert I, Beneke M. Headache; 2005 Oct; 45(7):874-82. PubMed ID: 15985104 [Abstract] [Full Text] [Related]
3. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355 [Abstract] [Full Text] [Related]
4. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ, AEGIS Investigator Study Group. Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358 [Abstract] [Full Text] [Related]
5. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS. Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814 [Abstract] [Full Text] [Related]
6. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D. Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178 [Abstract] [Full Text] [Related]
7. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Goadsby PJ. Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331 [Abstract] [Full Text] [Related]
8. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Winner P, Landy S, Richardson M, Ames M. Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449 [Abstract] [Full Text] [Related]
9. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Diener HC, Gendolla A, Gebert I, Beneke M. Eur Neurol; 2005 Nov; 53 Suppl 1():41-8. PubMed ID: 15920337 [Abstract] [Full Text] [Related]
10. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA. Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159 [Abstract] [Full Text] [Related]
11. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M. Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050 [Abstract] [Full Text] [Related]
12. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Diamond ML, Cady RK, Mao L, Biondi DM, Finlayson G, Greenberg SJ, Wright P. Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046 [Abstract] [Full Text] [Related]
13. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Cephalalgia; 2008 Apr; 28(4):383-91. PubMed ID: 18294251 [Abstract] [Full Text] [Related]
15. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Winner P, Adelman J, Aurora S, Lener ME, Ames M. Clin Ther; 2006 Oct; 28(10):1582-91. PubMed ID: 17157114 [Abstract] [Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S, Byrd S. Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463 [Abstract] [Full Text] [Related]
17. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ, AIMS Investigators. Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101 [Abstract] [Full Text] [Related]
18. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability. Von S. Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907 [Abstract] [Full Text] [Related]
19. Sumatriptan and naproxen sodium for the acute treatment of migraine. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Headache; 2005 Sep; 45(8):983-91. PubMed ID: 16109111 [Abstract] [Full Text] [Related]
20. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, AEGIS Investigator Study Group. Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700 [Abstract] [Full Text] [Related] Page: [Next] [New Search]